» Articles » PMID: 38203661

GLIS1, Correlated with Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jan 11
PMID 38203661
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) is a prevalent malignant disease and the primary reason for cancer-related mortality among men globally. GLIS1 (GLIS family zinc finger 1) is a key regulator in various pathologies. However, the expression pattern, clinical relevance, and immunomodulatory function of GLIS1 in PCa remain unclear. In this study, GLIS1 was discovered to serve as a key gene in PCa by integrating mRNA and miRNA expression profiles from GEO database. We systematically explored the expression and prognostic values of GLIS1 in cancers using multiple databases. Additionally, we examined the functions of GLIS1 and the relationship between GLIS1 expression levels and immune infiltration in PCa. Results showed that GLIS1 was differentially expressed between normal and tumor tissues in various cancer types and was significantly low-expressed in PCa. Low GLIS1 expression was associated with poor PCa prognosis. GLIS1 was also involved in the activation, proliferation, differentiation, and migration of immune cells, and its expression showed a positive correlation with the infiltration of various immune cells. Moreover, GLIS1 expression was positively associated with various chemokines/chemokine receptors, indicating the involvement in regulating immune cell migration. In summary, GLIS1 is a potential prognostic biomarker and a therapeutic target to modulate anti-tumor immune response in PCa.

Citing Articles

MTMR7 attenuates the proliferation and migration of pulmonary arterial smooth muscle cells in pulmonary hypertension by suppressing ERK/STAT3 signaling.

Wang J, Xuan B, Song B, Wang T, Lan C, Guo W Mol Cell Biochem. 2025; .

PMID: 39918745 DOI: 10.1007/s11010-025-05217-y.


Evaluating the predictive value of angiogenesis-related genes for prognosis and immunotherapy response in prostate adenocarcinoma using machine learning and experimental approaches.

Wang Y, He J, Zhao Q, Bo J, Zhou Y, Sun H Front Immunol. 2024; 15:1416914.

PMID: 38817605 PMC: 11137278. DOI: 10.3389/fimmu.2024.1416914.


Analysis and experimental validation of IL-17 pathway and key genes as central roles associated with inflammation in hepatic ischemia-reperfusion injury.

Tan S, Lu X, Chen W, Pan B, Kong G, Wei L Sci Rep. 2024; 14(1):6423.

PMID: 38494504 PMC: 10944831. DOI: 10.1038/s41598-024-57139-2.

References
1.
Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T . Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018; 175(7):1731-1743.e13. PMC: 6292840. DOI: 10.1016/j.cell.2018.10.014. View

2.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

3.
Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S, Santoni A . CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood. 2008; 111(7):3626-34. DOI: 10.1182/blood-2007-08-106203. View

4.
Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C . Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol. 2021; 12:669474. PMC: 8126720. DOI: 10.3389/fimmu.2021.669474. View

5.
Ding Y, Wu H, Warden C, Steele L, Liu X, van Iterson M . Gene Expression Differences in Prostate Cancers between Young and Old Men. PLoS Genet. 2016; 12(12):e1006477. PMC: 5189936. DOI: 10.1371/journal.pgen.1006477. View